Enterprise Value
629M
Cash
180.9M
Avg Qtr Burn
-34.6M
Short % of Float
8.57%
Insider Ownership
16.53%
Institutional Own.
76.48%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WVE-N531 Details Duchenne muscular dystrophy | Phase 2 Data readout | |
WVE-003 Details Huntington's disease | Phase 1/2 Update | |
WVE-006 Details Alpha-1 Antitrypsin Deficiency | Phase 1 Data readout | |
Phase 1 Initiation | ||
WVE-120101 (SNP1) Details Huntington's disease | Failed Discontinued | |
WVE-120102 (SNP2) Details Huntington's disease | Failed Discontinued | |
WVE-004 Details Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations | Failed Discontinued |